Federated Hermes Inc. Sells 107,719 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Federated Hermes Inc. cut its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 19.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 435,034 shares of the company's stock after selling 107,719 shares during the period. Federated Hermes Inc.'s holdings in Takeda Pharmaceutical were worth $5,760,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in TAK. Versant Capital Management Inc acquired a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at $26,000. Wilmington Savings Fund Society FSB acquired a new position in Takeda Pharmaceutical in the 3rd quarter worth $40,000. BNP Paribas Financial Markets increased its holdings in Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock worth $46,000 after purchasing an additional 2,596 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after purchasing an additional 1,976 shares during the period. Finally, Crowley Wealth Management Inc. bought a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at about $52,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Remove Ads

Takeda Pharmaceutical Stock Up 1.7 %

NYSE TAK traded up $0.25 during trading hours on Tuesday, hitting $14.55. 1,253,837 shares of the company traded hands, compared to its average volume of 1,851,995. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.37. The stock has a market capitalization of $46.28 billion, a price-to-earnings ratio of 36.36, a P/E/G ratio of 0.24 and a beta of 0.39. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The business's 50-day moving average is $14.48 and its 200-day moving average is $13.89.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Sell-side analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.